Giulia Baldon

Giulia Baldon

Auto-generated profile, based on publicly available information

Giulia Baldon

Università del Piemonte Orientale UPO, Novara, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2021 in Disease Markers
Verified
Journal Article
Open access
PDF file
MBMattia Bellan
Mattia Bellan
DADanila Azzolina
Danila Azzolina
EHEyal Hayden
Eyal Hayden
Gianluca GaidanoGianluca Gaidano
Gianluca Gaidano
Mario PirisiMario Pirisi
Mario Pirisi
PSPier Paolo Sainaghi
Pier Paolo Sainaghi
Introduction. The clinical course of Coronavirus Disease 2019 (COVID-19) is highly heterogenous, ranging from asymptomatic to fatal forms. The identification of clinical and laboratory predictors of poor prognosis may assist clinicians in monitoring strategies and therapeutic decisions. Materials and Methods. In this study, we retrospectively assessed the prognostic value of a simple tool, the complete blood count, on a cohort of 664 patients ( 260; 39%, median age 70 (56-81) years) hospitalized for COVID-19 in Northern Italy. We collected demographic data along with complete blood cell count; moreover, the outcome of the hospital in-stay was recorded. Results. At data cut-off, 221/664 patients (33.3%) had died and 453/664 (66.7%) had been discharged. Red cell distribution width (RDW) ( 10.4; ), neutrophil-to-lymphocyte (NL) ratio ( 7.6; ), and platelet count ( 5.39; ), along with age ( 87.6; ) and gender ( 17.3; ), accurately predicted in-hospital mortality. Hemoglobin levels were not associated with mortality. We also identified the best cut-off for mortality prediction: a was characterized by an odds ratio for in-hospital (2.40-4.82), while the OR for a

10 September 2020 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
EGEleonora Gambaro
Eleonora Gambaro
CGCarla Gramaglia
Carla Gramaglia
GBGiulia Baldon
Giulia Baldon
ECEmilio Chirico
Emilio Chirico
MMMaria Martelli
Maria Martelli
PZPatrizia Zeppegno
Patrizia Zeppegno
Background: Depressive disorders are the leading cause of disability worldwide and together with anxiety contribute to a very high burden of disease. Therefore, improving their treatment is a significant medical research target: The role of probiotics is a topic of great interest for the current research in this field.Objectives: To explore the current literature about the impact of probiotics on anxious and depressive symptoms.Methods: Scoping review following the PRISMA guidelines.Results: The selection process yielded 23 studies. Probiotics positively affected depressive symptomatology and anxiety symptoms according to 53.83% and 43.75% of the selected studies, respectively. Among the studies assessing inflammatory biomarkers, 58.31% found they were decreased after administration of probiotics.Conclusion: The results emerging from the existing literature about probiotic supplementation for depression treatment are encouraging, but further research is needed considering the shortage of clinical trials on this topic and the heterogeneity of the samples analyzed.